Home
Storia in 1 fonti
How HER2 biology is shaping next-generation cancer treatment
Combination strategies are rapidly redefining treatment for HER2-positive solid tumors. | HER2 combination strategies are evolving. Hear how biology and next-generation antibodies are redefining treatment.
Raccontata da
fiercepharma.com
Timeline cronologica
- ·
Fierce Pharma Asia—More China biotech hawkishness; Pfizer’s $10B Innovent deal; Astellas’ roadmap
As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to cur | As China-developed assets gain more attention from biopharma…
- ·
ASCO: With bispecifics on its heels, Incyte positions Monjuvi combo for first-line DLBCL
Seeking a share of the first-line diffuse large B-cell lymphoma (DLBCL) market, Incyte believes Monjuvi’s positive phase 3 results across patient subgroups will give it an edge…
- ·
ASCO: Sac-TMT’s massive phase 3 program has a jarring gap. Does Merck plan to close it?
Merck & Co.’s extensive clinical development scheme for its TROP2 antibody-drug conjugate (ADC) sac-TMT already
- ·
How HER2 biology is shaping next-generation cancer treatment
Combination strategies are rapidly redefining treatment for HER2-positive solid tumors. | HER2 combination strategies are evolving. Hear how biology and next-generation antibodies…
- ·
Fueling Pharma's AI Revolution with the Right Content, Governance and Licensing Strategy
Artificial intelligence is transforming pharma, but success depends on more than powerful algorithms. Download this whitepaper to learn how leading organizations are building…